# Chia Tai Tianqing Pharmaceutical Group trials: 53 (2026)

ClinicalTrials.gov lists 53 trials with Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. as lead sponsor, 28 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.: 53 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-nanjing-shunxin-pharmaceutical

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 53
- Recruiting or not yet: 28
- Read on: November 19, 2026

## Trials

The 25 newest of 53, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 24, 2026 | NCT07724366 | A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Psoriasis | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07724366) |
| June 17, 2026 | NCT07653685 | A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed... | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Colorectal Cancer | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07653685) |
| April 6, 2026 | NCT07512583 | Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07512583) |
| March 19, 2026 | NCT07483684 | A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed... | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | HER2 IHC3+ Advanced Colorectal Cancer | 142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07483684) |
| February 12, 2026 | NCT07406035 | A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Psoriatic Arthritis | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07406035) |
| September 18, 2025 | NCT07179679 | A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Multiple Myeloma | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07179679) |
| August 11, 2025 | NCT07113925 | A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Advanced Hematologic Malignancies | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07113925) |
| July 4, 2025 | NCT07052097 | Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 2 | Completed | Seasonal Allergic Rhinitis | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07052097) |
| July 2, 2025 | NCT07047365 | TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | HER2-positive Advanced Breast Cancer | 416 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07047365) |
| July 1, 2025 | NCT07044908 | TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | RAS/BRAF Wild Type Colorectal Cancer | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07044908) |
| June 29, 2025 | NCT07043751 | A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Advanced Malignant Tumors | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07043751) |
| June 29, 2025 | NCT07043725 | A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast... | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | HER2-positive Breast Cancer | 544 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07043725) |
| June 6, 2025 | NCT07008976 | Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Metastatic Breast Cancer | 246 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07008976) |
| June 4, 2025 | NCT07003074 | A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic... | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Breast Cancer | 642 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07003074) |
| May 8, 2025 | NCT06962267 | A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride... | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Pancreatic Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06962267) |
| April 29, 2025 | NCT06948539 | To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Breast Cancer, Lung Cancer, Colorectal Cancer | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06948539) |
| April 16, 2025 | NCT06929195 | Clinical Trial to Evaluate the Tolerance of TQB2210 Injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 | Completed | Advanced Malignant Tumours | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06929195) |
| February 13, 2025 | NCT06825494 | Clinical Studies for the Treatment of Advanced Solid Tumors | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 194 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06825494) |
| January 29, 2025 | NCT06798207 | A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Gynecological Tumors | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06798207) |
| January 23, 2025 | NCT06789289 | A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 2 | Active not recruiting | Chronic Obstructive Pulmonary Disease | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06789289) |
| January 10, 2025 | NCT06767813 | Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic... | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Pancreatic Neoplasms | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06767813) |
| January 10, 2025 | NCT06767800 | A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in... | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Gastroesophageal Adenocarcinoma | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06767800) |
| January 1, 2025 | NCT06754891 | Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's... | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Inflammatory Bowel Diseases | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06754891) |
| November 22, 2024 | NCT06700395 | A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Multiple Myeloma | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06700395) |
| November 4, 2024 | NCT06672263 | A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Chronic Myelogenous Leukemia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06672263) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 26 |
| Phase 1/2 | 6 |
| Phase 2 | 14 |
| Phase 3 | 7 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 24 |
| Completed | 8 |
| Unknown | 8 |
| Terminated | 5 |
| Not yet recruiting | 4 |
| Active not recruiting | 4 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 5 |
| Psoriasis | 4 |
| Pancreatic Neoplasms | 3 |
| Multiple Myeloma | 2 |
| Colorectal Neoplasms | 2 |
| Pulmonary Disease, Chronic Obstructive | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Rhinitis, Allergic, Seasonal | 1 |
| Osteosarcoma | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Asthma | 1 |
| Dermatitis, Atopic | 1 |
| Lymphoma, Mantle-Cell | 1 |
| Hemophilia A | 1 |
| Sinusitis | 1 |
| Lung Neoplasms | 1 |
| Hematologic Neoplasms | 1 |
| Inflammatory Bowel Diseases | 1 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 |
| Biliary Tract Neoplasms | 1 |
| Arthritis, Psoriatic | 1 |
| Non-alcoholic Fatty Liver Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Cuban restaurants in the United States](https://specstream.ai/data/businesses/cuban-restaurants/united-states)
- [Nursing schools in the United States](https://specstream.ai/data/businesses/nursing-schools/united-states)
- [Aluminum suppliers in the United States](https://specstream.ai/data/businesses/aluminum-suppliers/united-states)
- [French restaurants in the United States](https://specstream.ai/data/businesses/french-restaurants/united-states)
- [Remodeling contractors in the United States](https://specstream.ai/data/businesses/remodeling-contractors/united-states)
